| abstract |
The present application provides a phosphatidylcholine product represented by formula (I) and a fatty acid composition containing same. In formula (I), R 1 and R 2 are each independently selected from residues of saturated or unsaturated fatty acids having more than 12 carbon atoms; and R 1 and R 2 comprise an EPA residue and a DHA residue. The phosphatidylcholine product represented by formula (I) and fatty acid composition provided by the present application can improve damage of IBD model animal colon tissues to a certain extent, have certain anti IBD activity, and are superior to the first-line drug, sulfasalazine. |